CNBC reports that this would “dramatically expand the number of shots available to middle and high school students ahead of the next school year.”
We just announced that the Phase 2/3 study of our COVID-19 vaccine in adolescents has met its primary immunogenicity endpoint. In the study, no cases of COVID-19 were observed in participants who had received 2 doses of the vaccine: https://t.co/SHTokbDhKR pic.twitter.com/rqHEfmi9s9
— Moderna (@moderna_tx) May 25, 2021